[Caution] CagriSema trial ratios are fixed-dose, do not extrapolate to self-mixing
CagriSema trial ratios are fixed-dose, do not extrapolate to self-mixing — a position I have arrived at slowly and would like tested. Reading the trial literature on this without misleading yourself. Separate the monotherapy arms from the combination arms before you do anything else. They report different effect…
Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.
Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.
phase 3 data will change most of what gets said here
That result is preclinical. Worth flagging, since the thread has been reading it as human data.
Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.
Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.